ImmunoPrecise Antibodies 2025年第二季度每股收益C$(0.09)超过预期C$(0.10),销售额C$6.13M未达到预期C$6.44M

财报速递12-10
ImmunoPrecise Antibodies (NASDAQ:IPA)报告的季度每股亏损为$(0.09),超过了分析师一致预期的$(0.10),高出10%。与去年同期的每股亏损$(0.10)相比,这一数据增长了10%。公司报告的季度销售额为610万美元,未达到分析师一致预期的640万美元,低于预期4.88%。与去年同期的销售额615万美元相比,这一数据下降了0.41%。

以上内容来自Benzinga Earnings专栏,原文如下:

ImmunoPrecise Antibodies (NASDAQ:IPA) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.10) by 10 percent. This is a 10 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $6.13 million which missed the analyst consensus estimate of $6.44 million by 4.88 percent. This is a 0.41 percent decrease over sales of $6.15 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法